MicroRNA-101a-3p mimic ameliorates spinal cord ischemia/reperfusion injury

NEURAL REGENERATION RESEARCH, 2022 · DOI: https://doi.org/10.4103/1673-5374.335164 · Published: February 8, 2022

Simple Explanation

This study investigates the role of miR-101a-3p in spinal cord ischemia/reperfusion injury (SCII) using a rat model. The researchers found that miR-101a-3p expression decreased after SCII, while MYCN expression increased. They also found that miR-101a-3p targets MYCN. The study further showed that injecting an miR-101a-3p mimic reduced the expression of MYCN, p53, caspase-9, and interleukin-1β. The mimic also reduced the number of necrotic cells and improved Tarlov scores in rats with SCII. These findings suggest that miR-101a-3p mimic therapy could be a potential treatment option for spinal ischemia/reperfusion injury. The mimic appears to improve nerve cell apoptosis and inflammation by inhibiting MYCN and the p53 signaling pathway.

Study Duration

24 hours reperfusion

Participants

76 Sprague-Dawley rats

Evidence Level

Not specified

Key Findings

1
miR-101a-3p expression is significantly decreased in the spinal cord after ischemia/reperfusion injury, while MYCN expression is increased.
2
MYCN is a direct target of miR-101a-3p, as confirmed by dual-luciferase reporter assay.
3
Intrathecal injection of an miR-101a-3p mimic improves hind limb motor function and reduces cell apoptosis after spinal cord ischemia/reperfusion injury.

Research Summary

This study investigates the therapeutic potential of miR-101a-3p mimic in treating spinal cord ischemia/reperfusion injury (SCII) in rats. The research demonstrates that miR-101a-3p expression is reduced following SCII, whereas MYCN expression increases. The administration of miR-101a-3p mimic resulted in decreased expression of MYCN, p53, caspase-9, and interleukin-1β, along with reduced neuronal apoptosis and improved motor function. These findings highlight the neuroprotective effects of miR-101a-3p. The study concludes that miR-101a-3p mimic therapy may be a potential treatment option for spinal ischemia/reperfusion injury by inhibiting MYCN and the p53 signaling pathway, offering a novel approach for managing this condition.

Practical Implications

Therapeutic Potential

miR-101a-3p mimic therapy may be a potential treatment option for spinal ischemia/reperfusion injury.

Target Identification

MYCN is identified as a direct target of miR-101a-3p, providing a specific target for therapeutic intervention.

Signaling Pathway Modulation

The study suggests that the miR-101a-3p mimic protects against SCII-induced damage by inhibiting the MYCN-p53-caspase-9 signaling pathway and proinflammatory cytokine IL-1β production.

Study Limitations

1
The sample size should be increased to improve the accuracy of this study.
2
More time points after SCII should be observed to better understand the neuroprotective effect of the miR-101a-3p mimic.
3
More in vitro cell experiments are needed to understand the molecular mechanisms in more detail.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury